Literature DB >> 16955689

Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.

Frank C Odds1.   

Abstract

Basilea Pharmaceutica is developing BAL-8557, a water-soluble prodrug of the triazole BAL-4815, for the potential treatment of fungal infections. By August 2005, a phase II study in oral candidiasis was underway. In September 2005, phase III trials were planned for invasive Candida and mold infections, including aspergillus and zygomycetes.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16955689

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  10 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

Review 2.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

Review 3.  Resistance to antifungals that target CYP51.

Authors:  Josie E Parker; Andrew G S Warrilow; Claire L Price; Jonathan G L Mullins; Diane E Kelly; Steven L Kelly
Journal:  J Chem Biol       Date:  2014-08-27

4.  In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Authors:  Maria-Teresa Illnait-Zaragozi; Gerardo F Martínez; Ilse Curfs-Breuker; Carlos M Fernández; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

5.  Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

6.  In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Susanne Perkhofer; Veronika Lechner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

Review 7.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411

Review 8.  Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.

Authors:  Claudia Spampinato; Darío Leonardi
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

9.  Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.

Authors:  Suresh Ambati; Emma C Ellis; Jianfeng Lin; Xiaorong Lin; Zachary A Lewis; Richard B Meagher
Journal:  mSphere       Date:  2019-10-30       Impact factor: 4.389

Review 10.  Advances in Antifungal Drug Development: An Up-To-Date Mini Review.

Authors:  Ghada Bouz; Martin Doležal
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.